A PILOT FEASIBILITY STUDY OF A STEROID-SPARING ANTI-NAUSEA AND VOMITING REGIMEN WITH NETUPITANT/PALONOSETRON FOR PATIENTS WITH GERM CELL TUMOURS RECEIVING MULTI-DAY CISPLATIN-BASED CHEMOTHERAPY AT THE OTTAWA HOSPITAL

Registry ID

SPARROW-GC

Source registry

HEALTH_CANADA

Status

Pending

Study type

INTERVENTIONAL

Sponsor

OTTAWA HOSPITAL RESEARCH INSTITUTE

Last update

2026-01-12

Conditions

• GERM CELL TUMOUR

Related clinical trials

• A PHASE II TRIAL EVALUATING CHEMOTHERAPY FOLLOWED BY RESPONSE-BASED REDUCED RADIATION THERAPY FOR PATIENTS WITH CENTRAL NERVOUS SYSTEM GERMINOMAS
• A PHASE 2 TRIAL OF CHEMOTHERAPY FOLLOWED BY RESPONSE-BASED WHOLE VENTRICULAR & SPINAL CANAL IRRADIATION (WVSCI) FOR PATIENTS WITH LOCALIZED NONGERMINOMATOUS CENTRAL NERVOUS SYSTEM GERM CELL TUMOR
• PHASE 3 ACCELERATED BEP TRIAL: A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS
• A PHASE 3 STUDY OF ACTIVE SURVEILLANCE FOR LOW RISK AND A RANDOMIZED TRIAL OF CARBOPLATIN VS. CISPLATIN FOR STANDARD RISK PEDIATRIC AND ADULT PATIENTS WITH GERM CELL TUMOURS

View on source registry